Food Allergy Drug Pipeline Analysis Report 2025
Description
Food allergy is an immune system reaction to certain foods, potentially causing severe, life-threatening symptoms. It affects around 220 million people globally, with a significant unmet need for effective treatments beyond avoidance strategies and emergency epinephrine. Current therapeutic options remain limited, driving research into innovative drugs and therapeutics. Emerging drug candidates, including biologics targeting immune modulation, show promise in enhancing patient outcomes. This evolving landscape highlights the potential for more effective food allergy therapeutic products in the coming years.
Report Coverage
The Food Allergy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into food allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for food allergy. The food allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The food allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with food allergy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to food allergy.
Food Allergy Drug Pipeline Outlook
Food allergy is an immune system reaction to certain foods, triggering symptoms like hives, swelling, digestive issues, or even anaphylaxis. It occurs when the body mistakenly identifies a harmless food as a threat. Common allergens include peanuts, tree nuts, milk, eggs, soy, wheat, fish, and shellfish.
Food allergy management focuses on allergen avoidance and symptom control. Antihistamines can relieve mild reactions, while epinephrine is essential for anaphylaxis. Oral immunotherapy is an emerging treatment to build tolerance to allergens. Regular consultations with an allergist, accurate food labeling checks, and carrying emergency medication are vital steps to ensure safety and prevent severe allergic reactions.
Food Allergy Epidemiology
Food allergy affects approximately 220 million people globally, with significant regional variations. In the United States, it impacts up to 8% of children and 10% of adults. In the United Kingdom, 6% of adults, or 2.4 million individuals, have clinically confirmed food allergies. In Japan, prevalence rates reach 10% in infants, 5% in young children, and 4.5% in school children.
Food Allergy – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of food allergy drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total food allergy clinical trials.
Food Allergy – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the food allergy pipeline analysis include monoclonal antibodies, biologics, small molecules, peptides, immunotherapies, and others. The food allergy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for food allergy.
Food Allergy Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the food allergy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed food allergy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in food allergy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for food allergy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of food allergy drug candidates.
Drug: Ligelizumab
Ligelizumab, sponsored by Novartis Pharmaceuticals, is undergoing a Phase III extension study to evaluate its long-term safety and efficacy in food allergy treatment. This next-generation anti-IgE monoclonal antibody blocks the IgE/FcεRI pathway, reducing allergic inflammation. The study will assess symptom resolution, quality of life improvements, and the drug’s potential for long-term, self-administered treatment.
Drug: Remibrutinib
Remibrutinib, an oral BTK inhibitor, aims to reduce allergic reactions by modulating immune responses. Novartis Pharmaceuticals is conducting a Phase II study to evaluate the efficacy, safety, and tolerability of Remibrutinib in adults with peanut allergies. The study will assess participants' ability to tolerate increasing peanut protein doses after one month of treatment with varying drug doses.
Drug: IGNX001
IGNX001 is an IgG4 monoclonal antibody developed by IgGenix Australia Pty Ltd. It is currently undergoing a Phase I clinical trial for peanut allergy. The study aims to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. IGNX001 has demonstrated potent inhibition of peanut-induced mast cell degranulation, positioning it as a promising food allergy therapeutic product for improved allergy management.
Reasons To Buy This Report
The Food Allergy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for food allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into food allergy collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Food Allergy – Pipeline Insight Report
Food Allergy Market
Food Allergy Epidemiology
Global Allergy Treatment Market
Global Clinical Trials Market
Report Coverage
The Food Allergy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into food allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for food allergy. The food allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The food allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with food allergy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to food allergy.
Food Allergy Drug Pipeline Outlook
Food allergy is an immune system reaction to certain foods, triggering symptoms like hives, swelling, digestive issues, or even anaphylaxis. It occurs when the body mistakenly identifies a harmless food as a threat. Common allergens include peanuts, tree nuts, milk, eggs, soy, wheat, fish, and shellfish.
Food allergy management focuses on allergen avoidance and symptom control. Antihistamines can relieve mild reactions, while epinephrine is essential for anaphylaxis. Oral immunotherapy is an emerging treatment to build tolerance to allergens. Regular consultations with an allergist, accurate food labeling checks, and carrying emergency medication are vital steps to ensure safety and prevent severe allergic reactions.
Food Allergy Epidemiology
Food allergy affects approximately 220 million people globally, with significant regional variations. In the United States, it impacts up to 8% of children and 10% of adults. In the United Kingdom, 6% of adults, or 2.4 million individuals, have clinically confirmed food allergies. In Japan, prevalence rates reach 10% in infants, 5% in young children, and 4.5% in school children.
Food Allergy – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of food allergy drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Monoclonal Antibodies
- Biologics
- Small Molecules
- Peptides
- Immunotherapies
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total food allergy clinical trials.
Food Allergy – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the food allergy pipeline analysis include monoclonal antibodies, biologics, small molecules, peptides, immunotherapies, and others. The food allergy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for food allergy.
Food Allergy Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the food allergy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed food allergy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in food allergy clinical trials:
- Novartis Pharmaceuticals
- Regeneron Pharmaceuticals
- DBV Technologies
- Allergy Therapeutics
- IgGenix Australia Pty Ltd.
- InnoUp Farma S.L.
- Aravax Pty Ltd.
- Vedanta Biosciences, Inc.
- Parexel
- Genentech
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for food allergy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of food allergy drug candidates.
Drug: Ligelizumab
Ligelizumab, sponsored by Novartis Pharmaceuticals, is undergoing a Phase III extension study to evaluate its long-term safety and efficacy in food allergy treatment. This next-generation anti-IgE monoclonal antibody blocks the IgE/FcεRI pathway, reducing allergic inflammation. The study will assess symptom resolution, quality of life improvements, and the drug’s potential for long-term, self-administered treatment.
Drug: Remibrutinib
Remibrutinib, an oral BTK inhibitor, aims to reduce allergic reactions by modulating immune responses. Novartis Pharmaceuticals is conducting a Phase II study to evaluate the efficacy, safety, and tolerability of Remibrutinib in adults with peanut allergies. The study will assess participants' ability to tolerate increasing peanut protein doses after one month of treatment with varying drug doses.
Drug: IGNX001
IGNX001 is an IgG4 monoclonal antibody developed by IgGenix Australia Pty Ltd. It is currently undergoing a Phase I clinical trial for peanut allergy. The study aims to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. IGNX001 has demonstrated potent inhibition of peanut-induced mast cell degranulation, positioning it as a promising food allergy therapeutic product for improved allergy management.
Reasons To Buy This Report
The Food Allergy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for food allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into food allergy collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Food Allergy – Pipeline Insight Report
- Which companies/institutions are leading the food allergy drug development?
- What is the efficacy and safety profile of food allergy pipeline drugs?
- Which company is leading the food allergy pipeline development activities?
- What is the current food allergy commercial assessment?
- What are the opportunities and challenges present in the food allergy drug pipeline landscape?
- What is the efficacy and safety profile of food allergy pipeline drugs?
- Which company is conducting major trials for food allergy drugs?
- Which companies/institutions are involved in food allergy collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in food allergy?
Food Allergy Market
Food Allergy Epidemiology
Global Allergy Treatment Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Food Allergy
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Food Allergy
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Food Allergy: Epidemiology Snapshot
- 5.1 Food Allergy Incidence by Key Markets
- 5.2 Food Allergy – Patients Seeking Treatment in Key Markets
- 6 Food Allergy: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Food Allergy: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Food Allergy, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Food Allergy Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Food Allergy Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Ligelizumab
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: DBV712
- 10.2.3 Other Drugs
- 11 Food Allergy Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Remibrutinib
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Biological: PVX-108
- 11.2.3 Other Drugs
- 12 Food Allergy Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: IGNX001
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Food Allergy Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Food Allergy, Key Drug Pipeline Companies
- 14.1 Novartis Pharmaceuticals
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Regeneron Pharmaceuticals
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 DBV Technologies
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Allergy Therapeutics
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 IgGenix Australia Pty Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 InnoUp Farma S.L.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Aravax Pty Ltd.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Vedanta Biosciences, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Parexel
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Genentech
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
